Bard Associates Inc. Has $2.53 Million Stock Holdings in Viemed Healthcare, Inc. (NASDAQ:VMD)

Bard Associates Inc. grew its position in shares of Viemed Healthcare, Inc. (NASDAQ:VMD) by 1.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 345,052 shares of the company’s stock after acquiring an additional 3,762 shares during the quarter. Bard Associates Inc.’s holdings in Viemed Healthcare were worth $2,529,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in VMD. Evernest Financial Advisors LLC acquired a new position in Viemed Healthcare during the second quarter worth $66,000. Perkins Coie Trust Co acquired a new position in shares of Viemed Healthcare during the 3rd quarter worth about $73,000. Victory Capital Management Inc. raised its holdings in shares of Viemed Healthcare by 21.1% in the 2nd quarter. Victory Capital Management Inc. now owns 12,791 shares of the company’s stock valued at $84,000 after purchasing an additional 2,226 shares during the period. SG Americas Securities LLC acquired a new stake in Viemed Healthcare in the 3rd quarter valued at about $89,000. Finally, Price T Rowe Associates Inc. MD bought a new position in Viemed Healthcare during the first quarter worth about $97,000. 74.24% of the stock is owned by institutional investors.

Viemed Healthcare Price Performance

NASDAQ:VMD opened at $9.06 on Friday. Viemed Healthcare, Inc. has a 12-month low of $6.21 and a 12-month high of $10.44. The firm has a market capitalization of $352.80 million, a price-to-earnings ratio of 33.56 and a beta of 1.43. The stock’s 50 day moving average price is $8.31 and its two-hundred day moving average price is $7.53. The company has a quick ratio of 1.19, a current ratio of 1.31 and a debt-to-equity ratio of 0.03.

Viemed Healthcare (NASDAQ:VMD) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.02. The business had revenue of $58.00 million for the quarter. Viemed Healthcare had a net margin of 4.87% and a return on equity of 8.72%.

Insiders Place Their Bets

In other Viemed Healthcare news, Director Nitin Kaushal sold 30,000 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $9.56, for a total value of $286,800.00. Following the completion of the transaction, the director now directly owns 126,843 shares in the company, valued at approximately $1,212,619.08. This trade represents a 19.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Randy E. Dobbs sold 36,261 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $9.28, for a total value of $336,502.08. Following the sale, the director now owns 107,706 shares in the company, valued at approximately $999,511.68. This trade represents a 25.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 20.00% of the company’s stock.

Viemed Healthcare Company Profile

Viemed Healthcare, Inc, together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD.